We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
- Recent CLDX Stock Price: $24.75
- Yearly Gain for CLDX stock: -20.93%
- Market Cap for CLDX stock: $1.16B
- P/E Ratio for CLDX stock: -14.455
Will CLDX's stock price go up? Is there an accurate CLDX stock forecast available?
TipRanks.com reports that Celldex currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $66.50. The target pricing ranges from a high CLDX forecast of $73.00 down to a low forecast of $59.00. Celldex (CLDX)’s last closing stock price was $24.75 which would put the average price target at 168.69% upside.
In addition, TradingView issued a Sell rating for CLDX stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CLDX stock.
Other analysts covering CLDX include:
- Chris Howerton of Jefferies issued a Buy rating with the price target of $ 66 on 5 days ago
- Thomas Smith of SVB Securities issued a Buy rating with the price target of $ 68 on 5 days ago
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $ 73 on 5 days ago
- Sam Slutsky of LifeSci Capital issued a Buy rating with the price target of $ 68 on 11 months ago
If you are wondering if CLDX is a good stock to buy, here are 3rd party ratings for CLDX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 31% (76 out of 251)
What is the sentiment on the street regarding Celldex? (Current ratings compiled by TipRanks.com)
- News Sentiment for CLDX stock: Very Bullish
- Blogger Consensus for CLDX stock: Bullish
- Media Buzz for CLDX stock: Medium
- Insider Signal for CLDX stock: ―
- Investor Sentiment for CLDX stock: Negative
- Hedge Fund signal for CLDX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on CLDX stock including scouring the social networks like CLDX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CLDX stock chart >>
Summary: Talaris Therapeutics Inc. is a late-clinical stage cell therapy company. It involved in developing a method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. Talaris Therapeutics Inc. is based in BOSTON.
- Recent TALS Stock Price: $2.90
- Yearly Gain for TALS stock: -79.30%
- Market Cap for TALS stock: $120.24M
- P/E Ratio for TALS stock: -2.069
Will TALS's stock price go up? Is there an accurate TALS stock forecast available?
TipRanks.com reports that Talaris Therapeutics currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.67. The target pricing ranges from a high TALS forecast of $11.00 down to a low forecast of $7.00. Talaris Therapeutics (TALS)’s last closing stock price was $2.90 which would put the average price target at 198.97% upside.
In addition, TradingView issued a Sell rating for TALS stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on TALS stock.
Other analysts covering TALS include:
- Mani Foroohar of SVB Securities issued a Hold rating with the price target of $ 7 on 1 day ago
- Joshua Schimmer of Evercore ISI issued a Buy rating with the price target of $ 11 on 6 days ago
- n/a of n/a issued a n/a rating with the price target of n/a on n/a
- n/a of n/a issued a n/a rating with the price target of n/a on n/a
If you are wondering if TALS is a good stock to buy, here are 3rd party ratings for TALS stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 37% (91 out of 251)
What is the sentiment on the street regarding Talaris Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for TALS stock: Neutral
- Blogger Consensus for TALS stock: ―
- Media Buzz for TALS stock: Very High
- Insider Signal for TALS stock: ―
- Investor Sentiment for TALS stock: ―
- Hedge Fund signal for TALS stock: Neutral
The stock market is extremely volatile, and you need to do your own research on TALS stock including scouring the social networks like TALS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TALS stock chart >>
Summary: Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
- Recent AXSM Stock Price: $41.21
- Yearly Gain for AXSM stock: -38.46%
- Market Cap for AXSM stock: $1.60B
- P/E Ratio for AXSM stock: -11.083
Will AXSM's stock price go up? Is there an accurate AXSM stock forecast available?
TipRanks.com reports that Axsome Therapeutics currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $65.44. The target pricing ranges from a high AXSM forecast of $130.00 down to a low forecast of $27.00. Axsome Therapeutics (AXSM)’s last closing stock price was $41.21 which would put the average price target at 58.80% upside.
In addition, TradingView issued a Buy rating for AXSM stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AXSM stock.
Other analysts covering AXSM include:
- Marc Goodman of SVB Securities issued a Buy rating with the price target of n/a on 1 week ago
- Jason Gerberry of Bank of America Securities issued a Sell rating with the price target of $ 28 on 1 week ago
- Joseph Thome of Cowen & Co. issued a Buy rating with the price target of $ 130 on 1 week ago
- Chris Howerton of Jefferies issued a Buy rating with the price target of $ 77 on 1 week ago
If you are wondering if AXSM is a good stock to buy, here are 3rd party ratings for AXSM stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 31% (76 out of 251)
What is the sentiment on the street regarding Axsome Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for AXSM stock: Bullish
- Blogger Consensus for AXSM stock: Bullish
- Media Buzz for AXSM stock: Medium
- Insider Signal for AXSM stock: ―
- Investor Sentiment for AXSM stock: Neutral
- Hedge Fund signal for AXSM stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on AXSM stock including scouring the social networks like AXSM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AXSM stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================